{"id":714415,"date":"2022-11-22T16:34:26","date_gmt":"2022-11-22T21:34:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/"},"modified":"2022-11-22T16:34:26","modified_gmt":"2022-11-22T21:34:26","slug":"g1-therapeutics-announces-closing-of-offering-of-common-stock","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/","title":{"rendered":"G1 Therapeutics Announces Closing of Offering of Common Stock"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">RESEARCH TRIANGLE PARK, N.C., Nov.  22, 2022  (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. G1 Therapeutics\u00a0received $50,050,000 in gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Raymond James acted as joint book-running managers for the offering. Needham &amp; Company and Wedbush PacGrow acted as lead managers for the offering.<\/p>\n<p>The shares were offered pursuant to a \u201cshelf\u201d registration statement previously filed and declared effective by the Securities and Exchange Commission (the \u201cSEC\u201d). The final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC, Attn: Cowen and Company, LLC, c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone: (833) 297-2926 or by email: PostSaleManualRequests@broadridge.com; or from Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com.<\/p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <strong>About G1 Therapeutics<\/strong><br \/>\n        <br \/>G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the company\u2019s first commercial product, COSELA\u00ae (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.<\/p>\n<p>G1Therapeutics\u00ae and the G1 Therapeutics logo and COSELA\u00ae and the COSELA logo are trademarks of G1 Therapeutics, Inc.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to expectations for the commercial launch of COSELA\u00ae (trilaciclib), the therapeutic potential of COSELA (trilaciclib), G1 Therapeutics\u2019 ability to accelerate adoption of COSELA among top tier accounts, G1 Therapeutics\u2019 ability to generate data to maximize trilaciclib\u2019s applicability to future treatment paradigms, and G1 Therapeutics\u2019 reliance on partners to develop and commercial licensed products. In addition, COSELA (trilaciclib) may fail to achieve the degree of market acceptance for commercial success, and the impact of pandemics, such as COVID-19 (coronavirus), are based on G1 Therapeutics\u2019 expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics\u2019 actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics\u2019 filings with the U.S. Securities and Exchange Commission, including the \u201cRisk Factors\u201d sections contained therein and include, but are not limited to, G1 Therapeutics\u2019 ability complete a successful commercial launch for COSELA (trilaciclib); G1 Therapeutics\u2019 ability to complete clinical trials for, obtain approvals for and commercialize additional indications of COSELA and any of G1 Therapeutics\u2019 product candidates other than COSELA (trilaciclib); G1 Therapeutics\u2019 initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a commercial-stage company; and market conditions. Except as required by law, G1 Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p>G1 Therapeutics Contact:<\/p>\n<p>Jen Moses<br \/>Chief Financial Officer<br \/>919-930-8506<br \/>jmoses@g1therapeutics.com<\/p>\n<p>Will Roberts<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>919-907-1944<br \/>wroberts@g1therapeutics.com<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmU5ZTZiNDctYjMzZi00MzZkLWE4MDYtM2U3OGYwYjUyYmI3LTEwNDA2Nzg=\/tiny\/G1-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. G1 Therapeutics\u00a0received $50,050,000 in gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Raymond James acted as joint book-running managers for the offering. Needham &amp; Company and Wedbush PacGrow acted as lead managers for the offering. The shares &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;G1 Therapeutics Announces Closing of Offering of Common Stock&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-714415","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>G1 Therapeutics Announces Closing of Offering of Common Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"G1 Therapeutics Announces Closing of Offering of Common Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. G1 Therapeutics\u00a0received $50,050,000 in gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Raymond James acted as joint book-running managers for the offering. Needham &amp; Company and Wedbush PacGrow acted as lead managers for the offering. The shares &hellip; Continue reading &quot;G1 Therapeutics Announces Closing of Offering of Common Stock&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-22T21:34:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"G1 Therapeutics Announces Closing of Offering of Common Stock\",\"datePublished\":\"2022-11-22T21:34:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/\"},\"wordCount\":764,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/\",\"name\":\"G1 Therapeutics Announces Closing of Offering of Common Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=\",\"datePublished\":\"2022-11-22T21:34:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-closing-of-offering-of-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"G1 Therapeutics Announces Closing of Offering of Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"G1 Therapeutics Announces Closing of Offering of Common Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"G1 Therapeutics Announces Closing of Offering of Common Stock - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. G1 Therapeutics\u00a0received $50,050,000 in gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Raymond James acted as joint book-running managers for the offering. Needham &amp; Company and Wedbush PacGrow acted as lead managers for the offering. The shares &hellip; Continue reading \"G1 Therapeutics Announces Closing of Offering of Common Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/","og_site_name":"Market Newsdesk","article_published_time":"2022-11-22T21:34:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"G1 Therapeutics Announces Closing of Offering of Common Stock","datePublished":"2022-11-22T21:34:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/"},"wordCount":764,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/","name":"G1 Therapeutics Announces Closing of Offering of Common Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=","datePublished":"2022-11-22T21:34:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMjE4NyM1Mjc3MTc0IzIwMjkxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-closing-of-offering-of-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"G1 Therapeutics Announces Closing of Offering of Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/714415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=714415"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/714415\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=714415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=714415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=714415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}